MIRM Mirum Pharmaceuticals, Inc.

NASDAQ
$89.70

Mirum Pharmaceuticals, Inc. (MIRM) is expected to report earnings on November 9, 2026, after the market close. The consensus earnings estimate is a loss of $0.61 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -0.6% since its last earnings release on August 5, 2026.

Mirum Pharmaceuticals, Inc. Missed Consensus Estimates, Raises Guidance
Wednesday, August 5, 2026 · 4:01 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · 4:00 PM ET
Earnings Whisper
-
vs ($0.61)
Rev est $176.46M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $96.83

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.